Pharmaceuticals
MS Pharma Announces Strategic Growth Investment from Olayan Financing Company
Strategic Partnership to Accelerate Growth in Saudi Arabia and Across the MENA Region AMMAN, Jordan and RIYADH, Saudi Arabia, May 18, 2026 /PRNewswire/ -- MS Pharma today announced that Olayan Financing Company (OFC) has made a minority equity investment in the company. This partnership brings s...
2026-05-18 20:39
3715
Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease
* Congenital adrenal hyperplasia (CAH) and Cushing's disease (CD) are rare disorders characterized by excess adrenocorticotropic hormone (ACTH) produced in the brain1,2 * Current treatments are limited by suboptimal disease control and treatment-related complications3,4 * Asedebart (Lu AG13...
2026-05-18 17:10
3587
Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
Clearance Recognises CellDx-Tissue's Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Level Evidence NASHIK, India, May 14, 2026 /PRNewswire/ -- Datar Cancer Genetics (DCG), a global precision oncology company, today announced that ...
2026-05-14 23:58
4054
CHEPLAPHARM to Accelerate Global Supply Chain Digitalization with TraceLink MINT
The German pharmaceutical company unifies its digital partner network, laying the foundation for AI-driven supply chain orchestration BOSTON, May 14, 2026 /PRNewswire/ -- TraceLink, the world's largest Agentic Business Network, today announced that the German-based but globally active CHEPLAPHAR...
2026-05-14 22:00
3769
MEDIPOST's CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control
- Achieved statistical significance versus standard-of-care (SOC) control across all key efficacy endpoints in the 52-week study - Japan Phase 3 results strengthen CARTISTEM's® global commercial prospects, with Japan biologics license application (BLA) scheduled for 2H 2026 SEOUL, South Korea and...
2026-05-14 10:30
3883
Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody
CHENGDU, China, May 12, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) appro...
2026-05-13 08:00
4727
Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine
Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline. LONDON, May 12, 2026 /PRNewswire/ -- Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $2.1 Bi...
2026-05-12 22:27
3626
Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer
European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable transfusion independence, and no treatment-related serious adverse events in ESA-refractory lower-risk MDS Dr. Myint, a hematology leader and oncology drug-development executive, joins Halia ...
2026-05-12 20:39
3318
Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AI
SUZHOU, China, May 12, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK) announced that the Company has entered into a strategic collaboration agreement with Insilico Medicine ("Insilico", 03696.HK). Both parties will leverage their respective core strengths in siRNA drug...
2026-05-12 20:30
4213
New Data Show Gaps in Antiviral Pipeline Against High-Risk Viral Threats
Longitudinal analysis reveals clear gaps in global preparedness against emerging viral threats and future pandemics. CAMBRIDGE, Mass., May 12, 2026 /PRNewswire/ -- New global analysis of antiviral compounds released today has identified a critically thin pipeline of treatments in development tha...
2026-05-12 19:00
2363
Avalere Health expands to Japan with a full-service Advisory, Medical, and Marketing offering, led by industry veteran Junji Yokokawa
Avalere Health Japan is designed with the full healthcare experience in mind, launching with an elite integrated team that brings together market access, medical, and marketing specialists, along with strategic consulting expertise. TOKYO, May 11, 2026 /PRNewswire/ -- Avalere Health, a global str...
2026-05-11 13:30
2248
ACROBiosystems Launches Global License Solution Upgrade for HEK293 Functional Cell Lines, Streamlining Compliance to Accelerate Biopharmaceutical R&D
SEOUL, South Korea, May 11, 2026 /PRNewswire/ -- ACROBiosystems announced a major upgrade to its global license solution for HEK293 functional cell lines. Centered on customer value and empowering global biopharmaceutical innovation, the upgrade simplifies compliance workflows to support efficien...
2026-05-11 08:00
3283
ACROBiosystems Launches Global License Solution Upgrade for HEK293 Functional Cell Lines, Streamlining Compliance to Accelerate Biopharmaceutical R&D
TOKYO, May 11, 2026 /PRNewswire/ -- ACROBiosystems announced a major upgrade to its global license solution for HEK293 functional cell lines. Centered on customer value and empowering global biopharmaceutical innovation, the upgrade simplifies compliance workflows to support efficient drug discov...
2026-05-11 08:00
3295
The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA
CHENGDU, China, May 8, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") announced that the sNDA (the "Application") for the Company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) was accepted for review ...
2026-05-08 19:29
5727
ABEC Expands Process Sciences Group to Strengthen Bioprocess Optimization Capabilities
BETHLEHEM, Pa., May 6, 2026 /PRNewswire/ -- ABEC, a global leader in bioprocess engineering solutions, announced the expansion of itsProcess Sciences group, expanding its ability to help biopharmaceutical manufacturers accelerate development, reduce risk, and improve productivity across the biopr...
2026-05-06 22:09
3281
Ribo and Boehringer Ingelheim further progress their siRNA program for metabolic dysfunction-associated steatohepatitis (MASH)
SUZHOU, China and MÖLNDAL, Sweden, May 6, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB ("Ribo", HKEX: 6938) today announced the achievement of a further milestone. This marks the third key milestone achieved in the research collaboration with Boehringer ...
2026-05-06 19:32
4408
MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026
GUANGZHOU, China, May 6, 2026 /PRNewswire/ -- MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas, announced positive results from its Phase II clinical trial of QA102 in patients with intermediate dry ...
2026-05-06 08:28
3859
Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)
HONG KONG, May 6, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the 33rd European Congress on Obesity (ECO 2026), taking place May 12-15, 2026 in Istanbul, Türkiye. The presentations include a poster on...
2026-05-06 08:10
4132
Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1
* PEDMARQSI® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours * TGA registration provides an approved treatment option in an area of significant unmet me...
2026-05-06 05:01
3057
BostonGene Receives Frost & Sullivan's 2026 Global Company of the Year for Advancing in AI-Driven Multimodal Oncology Platforms
Recognition highlights BostonGene's leadership in improving drug development
decisions,
reducing risk and accelerating patient impact
SAN ANTONIO, May 5, 2026 /PRNewswire/ -- Frost & Sullivan
2026-05-05 22:00
3589
Week's Top Stories
Most Reposted
Sustainable Tourism Academy Celebrates 3,000-User Milestone in First Year with ASEAN Expansion and New Language Support
[Picked up by 319 media titles]
2026-06-29 12:41
MetaOptics Begins Shipment of Metalens Smartphone and AI Smart Glasses to European and Japanese Customers for Evaluation
[Picked up by 302 media titles]
2026-06-26 18:11Vietnam Explores Sustainable Aviation Fuel Development at International Conference in Hanoi
[Picked up by 301 media titles]
2026-06-25 14:33
SPHERE AX Partners with U.S. AI Semiconductor Company Blaize at the National Assembly
[Picked up by 293 media titles]
2026-06-24 18:00
BELLUSTAR TOKYO Ranked No. 10 Among Japan's Best City Hotels in Prestigious Award Chosen by Asia-Pacific Travelers
[Picked up by 290 media titles]
2026-06-24 12:00
Most Read
Korean Skincare Brand Meditherapy Tops Amazon U.S. Facial Serums, Breaking Into Beauty Best Sellers Top 20
2026-06-26 21:00
3756
National Book Store Partners with Anchanto to accelerate success across Online Channels & 260+ Retail Locations
2026-06-23 08:00
3416
TWSC Debuts at MWC Shanghai 2026: Full-stack Self-developed Storage Powers AI and Data Communications
2026-06-26 21:50
3374
Quantifind Announces $200 Million Growth Investment Led by Summit Partners to Advance AI-native Risk Intelligence and Governed Agentic Middleware for Modern Risk Operations
2026-06-26 21:00
3359
Farmmi, Inc. Announces Launch of Proposed Public Offering
2026-06-27 08:01
3354